| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Center for Experimental Research and Medical Studies (CERMS), 2 Department of Anatomy, Pharmacology and Forensic Medicine, and 3 Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy
Requests for reprints: Carola Ponzetto, Department of Anatomy, Pharmacology, and Forensic Medicine, University of Turin, C.so Massimo d'Azeglio 52, 10126 Turin, Italy. Phone: 39-011-670-7747; Fax: 011-39-011-670-7732; E-mail: carola.ponzetto{at}unito.it.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
A widely employed histologic classification of RMS defines three subtypes, differing from each other for body location, occurrence, mean patient age, and prognosis. Embryonal rhabdomyosarcoma (ERMS) is composed of spindle-shaped cells with a stromal rich appearance and it occurs mainly in the head and neck region, including the orbita. The alveolar subtype (ARMS) typically consists of small round densely packed cells, resembling pulmonary alveoli, and it occurs more often in the trunk and extremities. The pleomorphic variant has minor incidence and does not occur in pediatric patients (2).
Alveolar histology is an independent predictor of worse outcome: a 5-year survival rate of <30% has been reported in children with metastatic ARMS. The most relevant feature of this subtype is the presence of one of two possible chromosomal translocations, t(2;13)(q35;q14) and t(1;13)(p36;q14), which result in expression of the chimeric PAX3-FKHR and PAX7-FKHR transcription factors, respectively (3–6). In contrast to ARMS, no diagnostic genetic lesions have been identified in ERMS. However, ERMS are characterized by frequent loss of heterozygosity at the 11p15 locus, a region harboring the genes for insulin-like growth factor 2 (IGF2), H19, p57kip2, and associated with alterations of imprinting (2). Expression profiling of ARMS and ERMS has revealed that the two signatures differ widely, to the point that in the rare cases lacking the classic chromosomal translocation, it is possible to diagnose the ARMS subtype on the basis of the transcriptional profile alone (7).
The PAX3/PAX7-FKHR translocations yield fusion proteins which are thought to have enhanced transcriptional activity. They consist of the DNA binding domain of PAX3 or PAX7 linked to the transactivation domain of the FKHR transcription factor. Both PAX3 and PAX7 are involved in skeletal muscle development. PAX3 is a key regulator of myogenesis (8) whereas PAX7 is the master gene of satellite cells specification (9). In myogenic precursors, PAX3 activates transcription of several target genes, among which myoD, lady-bird, and c-met (10–12). The latter codes for a cell-surface receptor which, at limb level, mediates delamination of myoblast precursors from the epithelial dermomyotome and their migration in the limb bud. This occurs in response to the hepatocyte growth factor/scatter factor (HGF/SF) ligand. Both pax3 and c-met loss of function mutant embryos lack limb muscles (13, 14). Conversely, in embryos where the pax3 gene is replaced by the PAX3-FKHR cDNA, myogenic precursors overexpress Met and undergo ectopic delamination. This phenotype can be rescued by bringing the PAX3-FKHR allele in a Met-null background (12), thus indicating that Met is responsible for the aberrant PAX3-FKHR–induced delamination.
Met is highly expressed in ARMS cell lines established from human tumors (15) and HGF/SF promotes their motility and resistance to chemotherapy (16). Consistently, Met was found to be up-regulated in a murine model of ARMS, obtained by bringing a conditional knock-in PAX3-FKHR allele in an Ink4a/Arf–/– background (17, 18). Interestingly, Met seems to be expressed also in human ERMS, sometimes at levels comparable with those seen in ARMS (19, 20). ERMS lack the t(2;13)(q35;q14) translocation, but in this case, MET transcription is likely to be driven by the wild-type form of either PAX3 or PAX7, one of which seems to be always up-regulated in this tumor type (21). Furthermore, by bringing in an Ink4a/Arf–/– background transgenic mice ectopically expressing HGF/SF, a highly penetrant model of ERMS has been obtained (22).
The evidence described above suggests that, in spite of their distinct molecular profiles, histology, and clinical outcome, Met may have a role not only in ARMS, which carry a dominant genetic lesion in an upstream transcription factor but also in ERMS, where the molecular mechanisms responsible for PAX3/PAX7 up-regulation are more elusive.
In this work, we first established that Met is an essential mediator of the oncogenic properties of PAX3-FKHR by showing that HGF/SF rescued the ability of PAX3-FKHR–expressing cells to grow in soft agar in low serum, and that fibroblasts from mutant mouse embryos expressing a signaling-dead Met receptor (MetD/D; ref. 14) were unable to form colonies following PAX3-FKHR transduction. We then used lentiviral-mediated inducible RNA interference to find out whether Met is essential for the survival of RMS cell lines, both alveolar and embryonal. Doxycycline-induced down-regulation of the Met receptor significantly affected proliferation, survival, invasiveness, and anchorage-independent growth of both ARMS and ERMS cells. Finally, we proved that Met down-modulation can arrest tumor growth also in vivo by treating with doxycycline nude mice bearing xenotransplants of RMS transduced with the inducible lentivirus. Histologic analysis of the regressing tumors showed that Met silencing was accompanied by an increase in apoptotic and a reduction in proliferating cells. These data indicate that Met may be necessary for RMS maintenance and suggest that Met-directed therapies may be effective in the treatment of RMS.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cells. Human RMS cells of embryonal (RD, RD18, and CCA) and alveolar (SJ-RH30, SJ-RH4, and RMZ-RC2) histotype and HER-2/neu-driven murine RMS cells were provided by Dr. Pier-Luigi Lollini (Amedeo Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy). GTL-16 cells are a gastric carcinoma cell line which overexpresses Met (23); NIH 3T3 fibroblasts were provided by Dr. Paola De Filippi (Department of Genetics, Cell Biology and Biochemistry, University of Turin, Turin, Italy); and 6647 Ewing's sarcoma cells were provided by Dr. Roberto Chiarle (Center for Experimental Research and Medical Studies (Turin, Italy)). C2C12 myoblasts, mouse embryonal fibroblasts (MEF), and HEK 293T cells were grown in DMEM (Euroclone) supplemented with 10% fetal bovine serum (Euroclone, Pero, Italy) and incubated at 37°C in a 7% CO2-water–saturated atmosphere. MetD/D Ink4a–/– and control Met+/+ Ink4a–/– mouse embryo fibroblasts were prepared from day 14.5 embryos according to standard procedures (24). Briefly, mothers were sacrificed at day 14.5 post coitum, the head and the red organs of embryos were removed, then the torso was minced and dispersed in 0.25% trypsin for 45 minutes at 37°C with gentle agitation. Cells were grown in DMEM supplemented with 10% FBS for two population doublings and then frozen.
Antibodies. Antihuman Met (C-12), antimouse Met (B-2), anti–extracellular signal-regulated kinase (ERK) 2 (C-14), anti-p53 (FL-393), anti-NF
B p65 (C-20), and anti–eukaryotic translation initiation factor 2
(eIF2; FL-315) were from Santa Cruz Biotechnology (Santa Cruz, CA); anti--tubulin (B-5-1-1) and anti–diphospho-ERK-1/2 (M-8159) were from Sigma-Aldrich (St. Louis, MO); anti–phospho-Akt (Ser473), anti-Akt, anti–cleaved caspase 3 (Asp175), anti–cleaved caspase 7 (Asp198), and anti–phospho-Met (Tyr1234/1235) were from Cell Signaling Technology (Danvers, MA); anti–green fluorescent protein (GFP) was from Molecular Probes (Eugene, OR); anti–phospho-eIF2 (Ab18) was from Oncogene Research (San Diego, CA); and anti-Ki67 was from Novocastra (Newcastle, United Kingdom).
Vector construction. The pSUPER vector containing the Met-specific short hairpin RNA (shRNA) M3 (25) was kindly provided by Dr. Silvia Giordano (IRCC, University of Turin). The pSUPER vector containing the TM2 control sequence was previously described (26). Constitutive Lenti-M3 was generated by subcloning the H1-RNA-promoter-M3 shRNA cassette from pSUPER in EcoRV-XhoI sites of the vector pCCL.sin.PPT.hPGK.GFPWpre (27). Conditional Lenti-M3 was generated by subcloning the H1-RNA-promoter-M3 shRNA cassette from pSUPER in EcoRI-CIaI sites of the vector pLVTH. pLVTH and LV-tTR-KRAB were kindly provided by Dr. Didier Trono (Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland). PLKO.1 lentiviral vectors expressing the shRNAs against PAX3 (NM_000438) were purchased from Open Biosystems (Huntsville, AL). PBabe-puro/PAX3-FKHR was kindly provided by Dr. Beat W. Schafer (Department of Pediatrics, Division of Oncology, University Children's Hospital, Zurich, Switzerland). PBabe-puro/eGFP construct was generated by subcloning the eGFP from pBI-EGFP (Clontech, Mountain View, CA) in BamHI-SalI sites of pBabe-puro MCS.
Lentiviral-retroviral vectors production and in vitro transduction. High titer lentiviral vector stock was produced in 293T cells by calcium phosphate–mediated transient transfection of the modified transfer vector pCCL.sin.PPT.hPGK.GFPWpre and packaging vectors pMDLg/pRRE, pRSV-Rev, and pMD2.VSVG; pPLVTH and LV-tTR-KRAB were cotransfected with pCMV-dR8.74, pRSV-Rev, and pMD2.VSVG packaging vectors. Supernatants were harvested after 30 hours, filtered through 0.22-µm pore size filters (Millipore, Billerica, MA) and used directly or after concentration by ultracentrifugation (50,000 x g for 2 hours). Virus titers were assessed by transducing HeLa cells with serial dilutions of viral stocks. RMS cells (1 x 105 in 35-mm diameter culture dishes) were transduced with virus plus 8 µg/mL polybrene. The medium was changed 24 hours after infection. Infectivity was determined after 72 hours by fluorescence-activated cell sorting (FACS) analysis of EGFP/dsRED2–positive cells. Retroviral supernatants were produced in Phoenix cells (28) by calcium phosphate–mediated transfection with 15 µg of retroviral plasmid. Supernatants were harvested after 48 and 72 hours from transfection and the medium containing viruses was filtered through 0.22-µm pore size filters. Cells (1 x 105 in 35 mm diameter culture dishes) were transduced with 1 mL of supernatant supplemented with 4 µg polybrene. Cells were grown until subconfluence, then trypsinized and replated in 10-cm dishes where puromycin selection was applied for 4 days.
Western blot. Cells were washed with ice-cold PBS, lysed, and scraped in lysis buffer [20 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 1 mmol/L ß-glycerolphosphate] with Protease Inhibitor Cocktail and 1 mmol/L sodium-orthovanadate. Protein lysates were cleared of cellular debris by centrifugation at 4°C for 10 minutes at 12,000 x g, quantified using Bio-Rad (Hercules, CA) protein assay, resolved in 10% SDS-PAGE gels, and transferred to Hybond-C Extra nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ). Proteins were visualized with horseradish peroxidase–conjugated secondary antibodies and Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL). For immunoprecipitation, each sample was precleared by using protein A/G-agarose (Santa Cruz Biotechnology). Immunoprecipitation was done overnight at 4°C using 1 mg primary antibody anti-mouse Met (B-2). Protein A/G-agarose (20 µL) was then added and incubation continued for 2 hours at 4°C. Protein A/G-agarose was collected, washed thrice with lysis buffer, and resuspended in SDS-gel sample buffer.
Cell proliferation assay. Cells were seeded in 96-well plates at a density of 2 x 103 per well in the presence or absence of doxycycline (20 ng/mL). Cell proliferation was evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide labeling reagent (Roche, Indianapolis, IN) or by counting cells in a Burker's hemocytometer chamber. The number of cells at day 1 was set at 100%.
Semiquantitative reverse transcription-PCR. PCR was done according to standard procedures. RNA was extracted from RMS cells by Trizol (Invitrogen, Carlsbad, CA). Total RNA, 0.4 µg, was used for reverse transcription by SuperScript III Reverse Transcriptase (Invitrogen) according to the instructions of the manufacturer. cDNA was then amplified using the following primers: actin-s 5'-GTGGACAGCGAGGCCAGGATG-3' and actin-as 5'-AGATCACTGCCCTGGCACCCA-3 for actin; PAX3-s 5'-AGAGGAAACAGCGCAGAAGCCG-3' and PAX3-as 5'-TGCTTCCTCCATCTTGCACGGC-3' for PAX3; HGF-s 5'-CAGCATGTCCTCCTGCATCTCC-3' and HGF-as 5'-TCGTGTGGTATCATGGAACTCC-3' for HGF. PCR reaction was done using the following variables: 94°C 1 minute, 61°C 30 seconds, 72°C x 30 seconds for 35 cycles. Relative intensity between actin fragments was used to verify if equal amounts of cDNA template were used.
Anchorage-independent cell growth assay. Cells were suspended in 0.35% type VII low melting agarose in DMEM (10% or 2% FBS) at 2 x 104 per well and plated on a layer of 0.7% agarose in DMEM (10% or 2% FBS) in six-well culture plates and cultured at 37°C with 7% CO2 with or without human recombinant HGF (4 ng/mL). HGF-containing medium was replaced every 5 days. After 2 weeks, colonies >100 µm in diameter were counted.
In vitro invasion assay. Invasiveness was examined by using the membrane invasion culture system (Transwell polycarbonate membranes 6.5 mm diameter, 8 µm pore size; Costar, Cambridge, MA) according to the standard protocol. Briefly, RMS cells were grown in the presence or absence of doxycycline (20 ng/mL) for 48 hours and 2 x 105 cells were seeded onto the upper well of transwells previously coated with 50 µL of Matrigel Basement Membrane Matrix (Becton Dickinson, Franklin Lakes, NJ). After 48 hours, the noninvasive cells on the upper surface of the membrane were removed with a cotton swab. Cells that migrated through the Matrigel matrix and attached to the lower surface of membrane were fixed with 11% glutaraldeyde, stained with cresyl violet, solubilized in 10% acetic acid solution, and quantified by spectrophotometrical analysis (595 nm).
Immunohistochemistry. Tumor samples were collected at the indicated times, fixed, and embedded in paraffin. Sections were rehydrated and processed with four antigen retrieval cycles of 5 minutes each in microwave oven (800 W) in citrate buffer (pH 6). After blocking for 1 hour at room temperature with 0.1% Triton X-100 and 10% normal goat serum in PBS, the sections were incubated with primary antibodies in the same solution at room temperature overnight. Primary antibodies were added at a dilution of 1:300. Sections were further processed with biotinylated secondary antibodies (1:300) and the avidin-biotin-peroxidase complex (ABC, Vector, Burlingame, CA) and finally visualized with 3,3'-diaminobenzidine (Roche).
Apoptosis analysis. Apoptosis was measured by flow cytometry after staining with Annexin V. Cells (1 x 105) were trypsinized, washed in PBS, and incubated for 15 minutes at 37°C in HEPES buffer solution [10 mmol/L HEPES (pH 7.4), 140 mmol/L NaCl, 2.5 mmol/L CaCl2] with 2.5 µL biotin-conjugated Annexin V (BD PharMingen Biosciences, San Diego, CA). Annexin V binding was revealed by additional incubation with 0.5 µL streptavidin-allophycocyanin (BD PharMingen Biosciences). Cells were analyzed by FACScan using CellQuest Software (BD PharMingen Biosciences).
In vivo tumorigenesis assay. Cells were trypsinized and resuspended at 1 x 107/mL in sterile PBS. One hundred microliters were injected s.c. into the flank of female nu/nu mice (Charles River, Wilmington, MA). Tumor dimensions were measured with vernier calipers every 3 days and tumor volumes were calculated as the volume of a sphere. Conditional anti-Met shRNAs were induced in mice using 1 mg/mL doxycycline in drinking water.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Constitutive and inducible lentiviral expression of a shRNA against Met (M3) down-regulates the Met receptor in RD18 ERMS cells. To study Met function in RMS, we first assessed the level of expression of the receptor and its ligand in different RMS cells. Both ERMS (RD, RD18, and CCA) and ARMS cells (SJ-RH4, SJ-RH30, and RMZ-RC2) expressed Met (Fig. 2A
). In these cells, the Met receptor was phosphorylated at confluence when the medium became conditioned by the low amounts of released HGF/SF (Fig. 2A; ref. 16). To verify whether Met silencing could affect their viability, we infected the RMS cells with a lentiviral vector that leads to constitutive expression of an anti-Met shRNA (M3) and EGFP as a marker (26, 27, 30). Biochemical analysis of RD18-transduced cells showed that Met was specifically down-regulated in a dose-dependent manner whereas expression of other endogenous proteins was unaffected (Fig. 2B). Furthermore, we did not observe any up-regulation of the phosphorylated form of eIF2, a signal of activation of the IFN-mediated response that is occasionally elicited by double-stranded RNA. Surprisingly, in RD18 cells, constitutive Met down-regulation induced a proliferative block followed by apoptosis (data not shown). To rule out the possibility that this effect could be due to the lentiviral vector, we decided to use an inducible system (requiring co-infection with two lentiviruses, LV-tTR-KRAB and LV-THshRNA-M3) in which the expression of the anti-Met shRNA was doxycycline dependent (31). In a first series of experiments, we tested the ability of this system to down-regulate the expression of Met receptor in RD18 ERMS cells. The cells, cotransduced with LV-tTR-KRAB and LV-THshRNA-M3, in the absence of doxycycline, expressed Met at levels comparable to those of wild-type cells because the tTR-KRAB protein repressed the production of the anti-Met shRNA (Fig. 2C). In contrast, doxycycline addition to the culture medium of the double-transduced cells resulted in a Met down-modulation as robust as that observed in RD18 cells constitutively expressing the M3 shRNA sequence. After 1 day of drug administration, Met was already strongly down-regulated (Fig. 2C). Concomitantly, the downstream response to HGF, exemplified by phosphorylation of Akt and ERK, was reduced (Fig. 2C).
|
|
Finally, biochemical analysis showed a strong correlation between Met down-modulation and activation of the apoptotic pathway in RMS cells. After 3 days of doxycycline administration, when Met was almost completely silenced, activation of caspase 3 and 7 became detectable (Fig. 3C). To further confirm the specificity of these results, we transduced positive and negative control cell lines with the constitutive M3 lentivirus. As a positive control, we used the U87 glioblastoma cell line, known to be sensitive to Met-directed rybozyme (32). As negative controls, we used RMS cells derived from a HER-2/neu transgenic mouse line (33), C2C12 myoblasts (which express Met), and Ewing's sarcoma cells (which do not express Met). Whereas Met down-regulation caused massive cell death in U87 cells (data not shown), it did not induce either alteration of the proliferation rate or apoptosis in all other control cells (Supplementary Fig. S1).
Conditional Met silencing induces inhibition of invasiveness in vitro and block of anchorage-independent growth. We next investigated if conditional Met silencing could cause reversion of the oncogenic properties of ERMS and ARMS cells (invasiveness and anchorage-independent growth). To analyze the invasive ability of RMS cells, we did Transwell assays. After 2 days of doxycycline administration, cells were plated in the upper well of transwells, previously coated with Matrigel, and cell migration to the other side of the filter was evaluated after 48 hours. Met silencing rapidly reduced the rate of migration across the extracellular matrix (Fig. 4A ). We next examined how our conditional Met silencing could affect the ability of RMS cells to grow in soft agar. As expected, the number of anchorage-independent colonies was markedly decreased in ERMS and ARMS cells in which Met had been conditionally silenced whereas no reduction was measured in uninduced M3 cells and in cells transduced with the control TM2 shRNA (Fig. 4B).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In this work, we first showed that Met expression is essential for PAX3-FKHR–mediated transformation. Met was up-regulated in PAX3-FKHR–transduced MEFs, NIH 3T3, and C2C12 cells, all of which acquired anchorage independence. However, PAX3-FKHR–transduced cells gave rise to colonies only in agar supplemented with 10% FBS, but not with 2% FBS. Soft-agar growth in low serum was rescued by chronic stimulation with HGF, proving that the oncogenic effect of PAX3-FKHR could be reconstituted by merely activating Met signaling. Furthermore, PAX3-FKHR did not induce formation of any colonies in fibroblasts derived from mutant mice expressing a signaling-dead Met receptor (Met D/D), yielding genetic proof that PAX3-FKHR indeed acts by activating the HGF-Met axis.
Up-regulation of Met in ARMS, which are characterized by the PAX3-FKHR translocation, is easily explained by the enhanced transcriptional activity of the chimeric protein. However, the receptor is also present in ERMS where its expression could depend on the sustained levels of PAX3 or PAX7 (21). We confirmed this hypothesis by showing that down-modulation of PAX3 in RD cells via RNA interference resulted in a concomitant reduction of Met protein (Supplementary Fig. S2).
Validation of the biological effect of a gene in cultured cells can be sought by gene silencing. We silenced Met expression in ERMS and ARMS cell lines by transducing them with a lentiviral system that allowed to control the expression of an anti-Met shRNA (M3) by doxycycline administration. Met silencing significantly impaired cell replication, survival, invasiveness, and anchorage-independent growth of RMS cells. The anti-Met shRNA also induced massive cell death in U87 glioblastoma cells, a line that was chosen as a positive control because its viability is known to be sustained by Met expression (32). Conversely, transduction with the M3 lentivirus of C2C12 myoblasts, murine HER-2/neu-dependent RMS cells, and Ewing's sarcoma cells did not induce any alteration of growth or apoptosis, indicating that Met acted as a dominant oncogene only in the cells where its silencing was crucial to viability. More precisely, silencing of the Met receptor impaired cell replication and increased apoptotic cell death. The ability of RMS cells to migrate through a Matrigel barrier and to form colonies in agar was also significantly reduced after Met knock-down. The effect on RMS proliferation was not seen by others following HGF stimulation (16); however, the apparent discrepancy may be due to the fact that we did our experiment in different conditions: 10% FBS, in absence of HGF, and by down-regulating the receptor.
When the effect of Met silencing was analyzed in vivo in a xenograft mouse model of RMS, turning on the M3 shRNA by doxycycline administration in the drinking water was sufficient to block tumor growth and to induce an impressive reduction of the tumor mass. Histologic analysis revealed that Met silencing was accompanied by an increase of apoptotic and by a reduction of Ki67-positive cells.
In conclusion, we have provided evidence for a role of Met in the maintenance and survival of both ARMS and ERMS. The finding of a common genetic element driving the two tumor types is somehow surprising because these tumors, besides being distinct for clinical presentation, histology, prognosis, and response to therapy, differ widely also in molecular terms, as shown by the presence of a specific genetic lesion only in ARMS and by their nonoverlapping gene expression profiles. A role for Met in ARMS, given the genetic evidence for a PAX3-FKHR-Met transcriptional axis, was perhaps predictable. It is intriguing to hypothesize that, due to its ability to confer invasive properties, Met could be functional to the worse aspect of this malignancy, its metastatic spread. It was more surprising to find that Met is also necessary for ERMS maintenance, given the milder nature of this malignancy and the absence of an obvious genetic lesion responsible for Met up-regulation. In this respect, it should be noted that others considered the possibility of finding activating point mutation in Met in ERMS, but the result of sequence analysis done on RMS cell lines was negative (16). On the other hand, a strong hint for Met involvement in ERMS was provided by the histology of the RMS found by Dr. G. Merlino's group in the murine model generated by bringing the HGF/SF transgene on an Ink4a/Arf–/– background (22).
Met signaling is known to keep myoblasts cycling and to delay their differentiation (36). This feature is likely to represent the link between the two tumors and may explain why the PAX3/FHKR genomic translocation is positively selected specifically in the myogenic lineage (37, 38). However, it is likely that the interactions and cross-talk of Met with other molecules, such as the IGF-I receptor (39), as well as its role in the establishment of the malignancy, may differ in the two tumor types.
Met has been implicated in a wide number of cancers (35) and a variety of Met-directed approaches of potential therapeutic value have been described (40). However, the experience of the epidermal growth factor receptor inhibitor gefitinib, which failed to show any benefit in two large randomized placebo-controlled trials including patients selected only on the basis of receptor expression, has taught us the importance, for the validation of a new drug, of identifying a cohort of patients where the targeted molecule is causal (41, 42). According to our data, both ARMS and ERMS are "addicted" to the Met oncogene and thus are likely to respond to Met-directed therapies. These may be particularly significant for the more aggressive forms of ARMS, which are among the most incurable childhood malignancies.
|
Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Roberto Piva and Elisa Vigna for technical help, Luigi Lollini for the RMS cell lines, and Silvia Giordano and Simona Corso for providing us with pSUPER-M3.
|
Footnotes |
|---|
Current address for P. Accornero: Department of Morphophysiology, via Leonardo da Vinci 44, 10095 Grugliasco, Turin, Italy.
Received 12/ 1/05. Revised 1/28/06. Accepted 3/ 3/06.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  D. Yan, X. D. Dong, X. Chen, L. Wang, C. Lu, J. Wang, J. Qu, and L. Tu MicroRNA-1/206 Targets c-Met and Inhibits Rhabdomyosarcoma Development J. Biol. Chem., October 23, 2009; 284(43): 29596 - 29604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oesch, D. Walter, M. Wachtel, K. Pretre, M. Salazar, M. Guzman, G. Velasco, and B. W. Schafer Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma Mol. Cancer Ther., July 1, 2009; 8(7): 1838 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kucharczak, S. Charrasse, F. Comunale, J. Zappulla, B. Robert, I. Teulon-Navarro, A. Pelegrin, and C. Gauthier-Rouviere R-Cadherin Expression Inhibits Myogenesis and Induces Myoblast Transformation via Rac1 GTPase Cancer Res., August 15, 2008; 68(16): 6559 - 6568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2) J. Biol. Chem., June 27, 2008; 283(26): 18158 - 18166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guo, J. Xie, E. Rubin, Y.-X. Tang, F. Lin, X. Zi, and B. H. Hoang Frzb, a Secreted Wnt Antagonist, Decreases Growth and Invasiveness of Fibrosarcoma Cells Associated with Inhibition of Met Signaling Cancer Res., May 1, 2008; 68(9): 3350 - 3360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Roeb, A. Boyer, W. K. Cavenee, and K. C. Arden PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1 PNAS, November 13, 2007; 104(46): 18085 - 18090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Slater and J. Shipley Clinical relevance of molecular genetics to paediatric sarcomas J. Clin. Pathol., November 1, 2007; 60(11): 1187 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Crepaldi, F. Bersani, C. Scuoppo, P. Accornero, C. Prunotto, R. Taulli, P. E. Forni, C. Leo, R. Chiarle, J. Griffiths, et al. Conditional Activation of MET in Differentiated Skeletal Muscle Induces Atrophy J. Biol. Chem., March 2, 2007; 282(9): 6812 - 6822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tsuda, I. J. Davis, P. Argani, N. Shukla, G. G. McGill, M. Nagai, T. Saito, M. Lae, D. E. Fisher, and M. Ladanyi TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition Cancer Res., February 1, 2007; 67(3): 919 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Grimm and M. A. Kay RNAi and Gene Therapy: A Mutual Attraction Hematology, January 1, 2007; 2007(1): 473 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
